virginia commonwealth university

Researchers develop and test new molecule as a delivery vehicle ...

EurekAlert! - Cancer  Tue, 08/02/2011 - 22:00

(Virginia Commonwealth University) A single compound with dual function -- the ability to deliver a diagnostic and therapeutic agent -- may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.


 

In the lab and clinic, VCU Massey develops a new therapy for blo...

EurekAlert! - Cancer  Wed, 06/01/2011 - 22:00

(Virginia Commonwealth University) Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.


 

Microbubble-delivered combination therapy eradicates prostate ca...

EurekAlert! - Cancer  Mon, 05/09/2011 - 22:00

(Virginia Commonwealth University) Cancer researchers are a step closer to finding a cure for advanced prostate cancer after effectively combining an anti-cancer drug with a viral gene therapy in vivo using novel ultrasound-targeted microbubble-destruction (UTMD) technology.


 

Discovery in liver cancer cells provides new target for drugs

EurekAlert! - Cancer  Mon, 03/21/2011 - 22:00

(Virginia Commonwealth University) Researchers at Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine have discovered a novel mechanism in gene regulation that contributes to the development of a form of liver cancer called hepatocellular carcinoma (HCC).

Currently, there is virtually no effective treatment for HCC, and this breakthrough identifies a promising new target for therapeutic intervention.


 

VCU Massey first to combine targeted agents to kill multiple mye...

EurekAlert! - Cancer  Wed, 02/09/2011 - 23:00

(Virginia Commonwealth University) Scientists at Virginia Commonwealth University Massey Cancer Center have developed a novel treatment strategy for multiple myeloma that pairs two targeted agents to kill cancer cells.


 

Nanoscale gene 'ignition switch' may help spot and treat cancer

EurekAlert! - Cancer  Tue, 12/14/2010 - 23:00

(Johns Hopkins Medical Institutions) In a proof of principal study in mice, scientists at Johns Hopkins and the Virginia Commonwealth University have shown that a set of genetic instructions encased in a nanoparticle can be used as an "ignition switch" to rev up gene activity that aids cancer detection and treatment.


 

VCU President Rao's Previous Code of Silence

Health Care Renewal  Mon, 12/06/2010 - 13:27

We recently posted about the code of silence imposed by Virginia Commonwealth University President Stephen Rao on his staff.  It turns out now that this was not his first exercise in imposing a code of silence.


 

A Confidentiality Clause or an Oath of Fealty?

Health Care Renewal  Tue, 11/30/2010 - 15:27

The advancement of modern scientific medicine depends on the search for and dissemination of truth. Academic medicine, like the rest of academia, ought to be based on openness, transparency, and academic freedom.

The 1940 American Association of University Professors (AAUP) Statement of Principles on Academic Freedom and Tenure opened with:


 

VCU Massey Cancer Center awarded $2.4 million grant from Virgini...

EurekAlert! - Cancer  Wed, 10/27/2010 - 22:00

(Virginia Commonwealth University) Virginia Commonwealth University Massey Cancer Center recently was awarded a two-year, $2.4 million grant from the Virginia Tobacco Indemnification and Community Revitalization Commission.


 

Key leukemia defense mechanism discovered by VCU Massey Cancer C...

EurekAlert! - Cancer  Wed, 09/29/2010 - 22:00

(Virginia Commonwealth University) Virginia Commonwealth University Massey Cancer Center researcher Steven Grant, M.D., and a team of VCU Massey researchers have uncovered the mechanism by which leukemia cells trigger a protective response when exposed to a class of cancer-killing agents known as histone deacetylase inhibitors.